Gilotrif and Companion Diagnostic Approved for NSCLC

Share this content:

The FDA announced the approval of Boehringer Ingelheim's Gilotrif (afatinib) for the treatment of metastatic non-small cell lung carcinoma (NSCLC) in patients whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations as detected by an FDA-approved test. The FDA has also approved to market Qiagen N.V.'s therascreen EGFR RQG PCR kit as a companion diagnostic to guide the use of Gilotrif.

Afatinib is an oral once-daily tyrosine kinase inhibitor that specifically inhibits epidermal growth factor receptor (EGFR or ErbB1), human epidermal receptor 2 (HER2 or ErbB2) and ErbB4. It is intended for patients whose tumors express the EGFR exon 19 deletions or exon 21 L858R substitution gene mutations.

The safety and effectiveness of Gilotrif were established in a clinical study of 345 participants with metastatic non-small cell lung carcinoma whose tumors harbored EGFR mutations. Participants were randomly assigned to receive Gilotrif or up to six cycles of the chemotherapy drugs pemetrexed and cisplatin. Participants receiving Gilotrif had a delay in tumor growth (progression-free survival) that was 4.2 months later than those receiving chemotherapy.

For more information visit Boehringer-Ingelheim.com or Qiagen.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs